Pharmacological correction of decompensated chronic heart failure with severe pulmonary hypertension at patients with congenital heart disease syndrome single ventricle

The prevalence of congenital heart disease (CHD) is 8-10 per 1000 live births. Of these, the incidence of defect formation of a single ventricle varies according to clinical data from 0.2% to 3.2% of all CHD. In addition to developmental features mediated mutagenic predictors exist and gender prerequisites for the formation of the defect. Pathophysiology of circulation in the single ventricle syndrome is caused by two factors: on the one hand, the mixing of blood in a single ventricle, and on the other, - transposition of great vessels. Powered by clinical observation: a woman of 33 years who at birth in 1981 was diagnosed with "single ventricle syndrome", at the time of curating complicated by chronic heart failure with high pulmonary hypertension. The best option selected correction using a combination of pharmacological groups: angiotensin-converting enzyme inhibitors (perindopril), calcium channel blockers (lercanidipine), diuretics (high sailing loop diuretics and aldosterone antagonist), phosphodiesterase type 5 inhibitors (sildanafil), anticoagulants (warfarin).